United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products in the United States and internationally. The company is headquartered in Hauppauge, New York.
| Revenue (TTM) | $10.94M |
| Gross Profit (TTM) | $5.21M |
| EBITDA | $2.39M |
| Operating Margin | 22.40% |
| Return on Equity | 21.70% |
| Return on Assets | 11.20% |
| Revenue/Share (TTM) | $2.38 |
| Book Value | $2.37 |
| Price-to-Book | 3.04 |
| Price-to-Sales (TTM) | 3.02 |
| EV/Revenue | 2.294 |
| EV/EBITDA | 10.51 |
| Quarterly Earnings Growth (YoY) | 46.00% |
| Quarterly Revenue Growth (YoY) | 15.80% |
| Shares Outstanding | $4.59M |
| Float | $2.96M |
| % Insiders | 35.85% |
| % Institutions | 20.79% |
Volatility is currently expanding
United-Guardian's rally reflects stronger sales, distribution expansion and recovering cosmetic demand, but valuation and trade risks may limit its near-term appeal.
UG reports higher y/y earnings and sales in Q1, driven by strong demand for Renacidin and increased purchases of cosmetic ingredients.
United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript
HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).
